Radiopharmaceutical firm DraxImage has received Food and Drug Administration clearance for a palladium-103 version of its BrachySeed therapy implant. BrachySeed Pd-103 is indicated for the treatment of prostate cancer and other localized tumors, such as in the head, neck, lung, pancreas, breast, and uterus, according to the Mississauga, ON-based company.
DraxImage launched BrachySeed I-125 in Canada and the U.S. this year. Following approval by the U.S. Nuclear Regulatory Commission, BrachySeed Pd-103 will become commercially available later this year, according to the company. The implant will be distributed in the U.S. by Cytogen, which also markets BrachySeed I-125 and the ProstaScint prostate cancer imaging agent.
By AuntMinnie.com staff writers
June 28, 2001
Related Reading
DraxImage gets new president, June 20, 2001
DraxImage files for approval for brachytherapy implant, April 27, 2001
DraxImage licenses Infecton Agent, March 15, 2001
Copyright © 2001 AuntMinnie.com
